Christopher Ryan Sullivan - 28 Mar 2025 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role: Chief Financial Officer
Signature: /s/ Donald R. Reynolds, by Power of Attorney
Issuer symbol: AVTX
Transactions as of: 28 Mar 2025
Net transactions value: -$61,631
Form type: 4
Filing time: 01 Apr 2025, 16:11:39 UTC
Previous filing: 30 Jan 2025
Next filing: 12 Dec 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AVTX	Common Stock	Options Exercise		+24,200	+403333%		24,206	28 Mar 2025	Direct	F1
transaction	AVTX	Common Stock	Tax liability	$61,631	-7,285	-30%	$8.46	16,921	28 Mar 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AVTX	Restricted Stock Units	Options Exercise	$0	-24,200	-33%	$0.000000	48,400	28 Mar 2025	Common Stock	24,200		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	On August 13, 2024, the Reporting Person was granted 72,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date.